These innovative compounds represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://declansvhx724734.actoblog.com/39903883/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide